Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus TOLECTIN DS.
FLURBIPROFEN SODIUM vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category D/X
Category C
NSAID
NSAID